APUS (Apimeds Pharmaceuticals Us) Insider Ownership: 11.08 % (As of Jul. 26, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $5.65
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Insider Ownership?

Apimeds Pharmaceuticals Us APUS -13.52% 14 Insider Ownership is 11.08 % as of Jul. 26, 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Apimeds Pharmaceuticals Us's insider ownership is 11.08%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Apimeds Pharmaceuticals Us's Institutional Ownership is 3.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Apimeds Pharmaceuticals Us's Float Percentage Of Total Shares Outstanding is 53.37%.

Apimeds Pharmaceuticals Us Insider Ownership Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us Insider Ownership Chart

Apimeds Pharmaceuticals Us Historical Data

The historical data trend for Apimeds Pharmaceuticals Us can be seen below:

2025-06-30 2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30
Insider Ownership 14.44 14.44 13.29 13.29 13.29 13.29 13.29 13.29 11.08 11.08
APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 11.08 % mean?
Apimeds Pharmaceuticals Us (APUS) has a Insider Ownership of 11.08 % as of Jul. 26, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Apimeds Pharmaceuticals Us and its competitors.
Is Apimeds Pharmaceuticals Us' Insider Ownership too high?
Apimeds Pharmaceuticals Us' current Insider Ownership is 11.08 %. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Insider Ownership compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' Insider Ownership of 11.08 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current Insider Ownership is 11.08 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Insider Ownership of 11.08 %. The current Insider Ownership is 11.08 %. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Insider Ownership is 11.08 % as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.65
Price